ACE and acute kidney injury: Patients with AKI were less likely to receive angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB) (39.6% for no AKI, 16.2% for AKI stage 1 and 20.2% for AKI stage ≥2, p < 0.001).